glycerol has been researched along with Lipid Metabolism, Inborn Error in 14 studies
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (64.29) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Nurjanah, S | 1 |
| Gerding, A | 1 |
| Vieira-Lara, MA | 1 |
| Evers, B | 1 |
| Langelaar-Makkinje, M | 1 |
| Spiekerkoetter, U | 1 |
| Bakker, BM | 1 |
| Tucci, S | 1 |
| Haglind, CB | 1 |
| Nordenström, A | 1 |
| Ask, S | 1 |
| von Döbeln, U | 1 |
| Gustafsson, J | 1 |
| Stenlid, MH | 1 |
| Ørngreen, MC | 1 |
| Ejstrup, R | 1 |
| Vissing, J | 1 |
| Kinman, RP | 1 |
| Kasumov, T | 1 |
| Jobbins, KA | 1 |
| Thomas, KR | 1 |
| Adams, JE | 1 |
| Brunengraber, LN | 1 |
| Kutz, G | 1 |
| Brewer, WU | 1 |
| Roe, CR | 1 |
| Brunengraber, H | 1 |
| Eriksson, A | 1 |
| Lindstedt, S | 1 |
| Ransnäs, L | 1 |
| von Wendt, L | 1 |
| Igal, RA | 1 |
| Coleman, RA | 1 |
| Galton, DJ | 4 |
| Reckless, JP | 3 |
| Taitz, LS | 1 |
| Clifton-Bligh, P | 1 |
| Cenedella, RJ | 1 |
| Crouthamel, WG | 1 |
| Di Donato, S | 1 |
| Garavaglia, B | 1 |
| Strisciuglio, P | 1 |
| Borrone, C | 1 |
| Andria, G | 1 |
| Gilbert, C | 1 |
| Kaye, J | 1 |
| Beaudet, AL | 1 |
| Lipson, MH | 1 |
| Ferry, GD | 1 |
| Nichols, BL | 1 |
| Burke, JA | 1 |
| Schubert, WK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)[NCT02036853] | Phase 2 | 20 participants (Actual) | Interventional | 2014-02-20 | Completed | ||
| Prevalence and Mutation Rate of Lipa Gene in LIPIGEN Subjects With Clinical Diagnosis of FH[NCT03984149] | 1,000 participants (Anticipated) | Observational | 2017-09-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and four yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -8.3 |
| Schedule B | -80.3 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and five yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | 23 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and one yr
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -6.5 |
| Schedule B | -110.5 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. (NCT02036853)
Timeframe: Baseline and 13 weeks
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | 4.4 |
| Schedule B | 189.5 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and 18 months
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -5.8 |
| Schedule B | -112.7 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and two yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -6 |
| Schedule B | -61.25 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and 26 weeks
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -5.6 |
| Schedule B | -78 |
A seizure diary was used to track date, type, number, and unusual presentation of seizures. Subjects were given a seizure diary at screening to record daily seizure activity for incremental periods of time. Unless otherwise waived, subjects complete this form daily during the screening period and for two weeks prior to each subsequent study visit. The table below represents the change in seizure frequency from baseline for each time point. (NCT02036853)
Timeframe: Baseline and three yrs
| Intervention | seizures/two weeks (Mean) |
|---|---|
| Schedule A | -0.8 |
| Schedule B | -77 |
1 review available for glycerol and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
The triglyceride storage diseases--a review.
Topics: Adenylyl Cyclases; Adipose Tissue; Child, Preschool; Chromatography, Thin Layer; Diagnosis, Differen | 1977 |
1 trial available for glycerol and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency.
Topics: Alanine; Blood Glucose; Carnitine O-Palmitoyltransferase; Creatine Kinase; Creatine Kinase, MM Form; | 2003 |
12 other studies available for glycerol and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
Heptanoate Improves Compensatory Mechanism of Glucose Homeostasis in Mitochondrial Long-Chain Fatty Acid Oxidation Defect.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Animals; Fatty Acids; Glucose; Glycerol; Heptanoates; Homeostasi | 2023 |
Increased and early lipolysis in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency during fast.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Age Factors; Biomarkers; Blood Glucose; Calorimetry, Indirect; Car | 2015 |
Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats.
Topics: Animals; Blood Glucose; Enteral Nutrition; Glycerol; Heptanoates; Infusions, Intravenous; Ketone Bod | 2006 |
Deficiency of glycerol kinase (EC 2.7.1.30).
Topics: Blood Glucose; Child; Fasting; Gas Chromatography-Mass Spectrometry; Glycerol; Glycerol Kinase; Huma | 1983 |
Neutral lipid storage disease: a genetic disorder with abnormalities in the regulation of phospholipid metabolism.
Topics: Cells, Cultured; Choline; Cytidine Diphosphate; Cytidine Diphosphate Choline; Diglycerides; Ethanola | 1998 |
Triglyceride storage disease. A report of two affected children associated with neurological abnormalities.
Topics: Abnormalities, Multiple; Adipose Tissue; Child, Preschool; Cyclic AMP; Deafness; Female; Glycerol; H | 1976 |
The hypertriglyceridaemias: a heterogeneous group of metabolic disorders.
Topics: Adipose Tissue; Diabetes Mellitus; Fasting; Glycerol; Humans; Insulin; Kinetics; Lipase; Lipid Metab | 1976 |
Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
Topics: Animals; Clofibrate; Dietary Fats; Disease Models, Animal; Glycerol; Glycerophosphates; Glycolates; | 1976 |
Multisystem triglyceride storage disease is due to a specific defect in the degradation of endocellularly synthesized triglycerides.
Topics: Cells, Cultured; Child, Preschool; Female; Fibroblasts; Glycerol; Humans; Ichthyosis; Infant; Lipid | 1988 |
Triglyceride storage disease. A group of inborn errors of triglyceride metabolism.
Topics: Adenylyl Cyclases; Adipose Tissue; Adult; Carbon Radioisotopes; Cyclic AMP; Female; Glucose; Glycero | 1974 |
Acid lipase in cultured fibroblasts: cholesterol ester storage disease.
Topics: Amniotic Fluid; Carbon Radioisotopes; Cells, Cultured; Cholesterol; Esters; Female; Fibroblasts; Gly | 1974 |
Deficient activity of hepatic acid lipase in cholesterol ester storage disease.
Topics: Cholesterol; Colorimetry; Fatty Acids; Glycerol; Humans; Lipase; Lipid Metabolism, Inborn Errors; Li | 1972 |